HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) (NCT01849588), a na phase 4 study. The primary outcome is Decline in HCV-RNA Level.

2. Clinical Question

In practical terms, the study asked whether a substantial decline in measured HCV-RNA occurred during sorafenib treatment in this small group. The title emphasizes HCV-RNA kinetics, or change over time, while the primary outcome reduces that trajectory to whether a participant crossed a specified decline threshold at any subsequent measurement. The registry also lists time to radiological tumor progression and overall survival as secondary outcomes. Their presence identifies additional questions of interest, but the record does not provide their results or analyses.

This distinction matters: a research question can be clear even when the registry does not show an answer. The available record describes the intended population, treatment, and endpoint, but it does not establish whether any participant met the primary endpoint.

3. Trial Design

This was a prospective Phase IV study sponsored by Massachusetts General Hospital. The registry describes a single-group model, no masking, and allocation as not applicable. Sorafenib was the only listed intervention, and the treatment arm description says it was taken orally twice per day. The study was not designed as a randomized comparison, so it has no like-for-like control group in the registry record.

The registry lists enrollment of 3 participants and a status of terminated. The recorded study start is 2013-05, and primary completion is listed as 2016-12. The reason for termination is not reported in the registry record. These dates and status describe the study’s administrative history; they do not explain why it ended or whether the planned research was completed as intended.

The clinical focus was HCV-RNA in people with chronic hepatitis C who were receiving sorafenib for advanced hepatocellular carcinoma. The study description says additional research blood samples would be drawn, and the primary endpoint concerns a decline between baseline and any subsequent measurement. The endpoint timeframe is up to 2 years. The registry record does not report a detailed visit schedule, the number or timing of blood draws, or laboratory procedures.

The registry lists time to radiological tumor progression and overall survival as secondary outcomes. It records four outcome measures overall, but provides no analyses. The record does not explain the intended statistical model, sample-size justification, monitoring plan, or analysis populations. Those gaps mean the design can be described at a high level, but its full operational and analytical plan cannot be reconstructed from the registry information.

Because this is a small, uncontrolled study, its role is descriptive and exploratory in the posted record. It can document what investigators intended to observe, but the absence of a comparator limits any assessment of how observed changes relate to what might have occurred without sorafenib.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Decline in HCV-RNA Level, measured over up to 2 years.

The primary endpoint is a participant count: the number who had a successful decline in HCV-RNA level. Success was defined as a decrease of at least two logs from baseline to any subsequent measurement, during a timeframe of up to 2 years. It is therefore a threshold-based outcome. It does not summarize the exact size or timing of every participant’s change, and it does not describe the average HCV-RNA trajectory.

A threshold can make an endpoint easier to interpret as a yes-or-no event for each participant. In general, this can be useful when a particular magnitude of change is considered meaningful for the research question. However, the registry record does not explain why this particular threshold was chosen, how HCV-RNA was measured, or how measurements at different times were handled.

The endpoint is used to examine a possible change in a virus-related laboratory marker during treatment. It is distinct from the listed secondary outcomes of time to radiological tumor progression and overall survival. A decline in HCV-RNA, by itself, would not establish a change in tumor status or survival. The record does not report the endpoint result, so it is not possible to say how many participants met the definition.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies the study structure and endpoint, but it does not describe a statistical analysis plan. The explanations below are general statistical context, not a reconstruction of methods that the investigators used. The record does not report an analysis method for the primary or secondary outcomes.

What a participant-count endpoint represents

The primary outcome is a count of participants who meet a stated definition. Each participant is classified according to whether HCV-RNA declined by at least two logs from baseline to any subsequent measurement. In general, a count endpoint can be summarized as the number meeting the definition alongside the number assessed. A proportion can also be informative, but the registry record does not report the primary count or denominator used in an efficacy analysis.

Because the endpoint is based on a threshold, it simplifies potentially detailed measurements over time into a participant-level event. That can help communicate whether a defined degree of decline occurred. It also discards information: someone just below the threshold and someone with little change would both fail the event definition, while the timing and persistence of a qualifying decline are not captured by the binary classification. The record does not say whether additional summaries of the continuous HCV-RNA measurements were planned.

Why repeated measurements raise analytical questions

The title refers to HCV-RNA kinetics, and the endpoint compares baseline with a subsequent measurement. In general, measurements taken repeatedly from the same participant are related rather than independent. An analysis of the full trajectory would need to account for the timing of measurements and their within-participant structure. The registry record does not report whether such an analysis was planned, how visit timing would be represented, or how variability in the measurements would be handled.

The primary endpoint’s phrase “any subsequent measurement” raises a further general issue: the chance of meeting a threshold may depend on how many measurements are made and when they occur. This does not establish that the study used any particular measurement schedule. The schedule and rules for selecting or interpreting later measurements are not reported in the registry record.

What a single-group design can describe

In a single-group study, a before-and-after comparison can describe changes among the people observed. Without a control group, it cannot directly estimate what would have happened to the same population under a different treatment or no treatment. General sources of ambiguity include natural changes over time, other care, and measurement variability. These are interpretive possibilities inherent in the design, not reported events in this trial.

For a small group, descriptive reporting of individual observations can be especially important because aggregate summaries may conceal how different participants’ courses were. The registry record does not include participant-level measurements or an analysis. It therefore does not allow the reader to examine individual trajectories or judge how representative a summary would be.

Uncertainty and confidence intervals

General statistical explanation: a confidence interval expresses the range of values compatible with an estimate under a specified method and its assumptions. It helps show precision; a point estimate alone does not. For a participant-count endpoint, uncertainty can be substantial when few people are observed, especially when the event count is near either end of the possible range. No confidence interval for the primary endpoint is reported in the registry record.

A confidence interval would not resolve the absence of a comparator. Precision and causal interpretation are different issues: a narrow interval around a descriptive estimate would still not establish what would have happened under another treatment. Here, neither a primary estimate nor its uncertainty is reported.

How to read the planning illustrations

The sample-size section is described as a planning illustration based on the observed effect, not as the study’s original design justification. The stated assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. For time-to-event outcomes, the tables give total events, while other tables give participants per arm.

Those assumptions describe hypothetical planning calculations. They do not describe this trial’s single-group structure, which has no randomized two-arm comparison in the registry record. A planning calculation under equal allocation should therefore not be mistaken for the actual enrollment plan or a comparison performed in this study. Sample-size illustrations are planning aids, not evidence that the study achieved a particular power. The registry record does not report its own sample-size justification.

General statistical context: normal approximations are convenient, but their suitability depends on the setting and data. For very small samples or sparse participant counts, approximation-based calculations may not represent uncertainty well. This observation does not alter the posted calculations; it is a reason to read their assumptions and purpose carefully.

The registry record does not report interim analyses, a prespecified statistical model, handling of missing measurements, or a formal analysis population. No such procedures should be inferred from the endpoint definition or planning assumptions. The posted results and methods should be distinguished from general statistical explanations and from hypothetical calculations.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Treatment Arm")
n      <- c(3)
events <- c(0)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Treatment Arm  3  0  0.0  0.0  70.8  0.0  56.1  0.6  60.2

11. Multiplicity, Missing Data and Analysis Populations

The record lists four outcome measures and identifies a primary endpoint, along with secondary outcomes of time to radiological tumor progression and overall survival. It records zero analyses. There is no reported analysis plan describing how these outcomes were tested or summarized, and multiplicity adjustment is not reported in the registry record.

Multiplicity is a general statistical concern when several outcomes or comparisons are examined: the more opportunities there are to identify an apparently notable result, the more important it becomes to understand which analyses were planned and how findings were interpreted. The record does not provide enough information to assess this issue for the study. The outcome count alone does not show that every measure was tested, nor does it establish which results were emphasized.

Missing-data methods are not reported in the registry record. The primary endpoint depends on baseline and subsequent measurements, but the information does not explain how participants with missing measurements, incomplete follow-up, or no qualifying later measurement were classified. The endpoint timeframe is up to 2 years, but that does not establish that all participants contributed data throughout that period.

Analysis populations are also not reported. The record does not specify whether all enrolled participants, participants who began treatment, or another defined group would be included in an efficacy analysis. It does not describe exclusions or the handling of participants who stopped treatment or follow-up. These omissions limit assessment of how any result would relate to the enrolled group.

Finally, interim analyses and stopping rules are not reported. The terminated status does not identify the reason for termination or whether any interim review took place. These details should remain unknown rather than inferred.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry’s safety figures list 3 participants at risk in the Sorafenib group. The serious adverse event count is 0 affected participants, while the separate count for other adverse events is 3 affected participants. These are counts within the reported group, not a comparison with another treatment, because no comparator group is listed.

The figures should be read as registry counts, not as a complete account of all possible safety outcomes. The information does not provide event descriptions, timing, severity grades, or participant-level details. It also does not explain the criteria used for categorizing events. The registry record does not report the number of deaths.

A zero count for serious adverse events in this small enrolled group does not establish that serious events cannot occur or quantify risk precisely. Conversely, the count of 3 participants with other adverse events does not, by itself, establish that sorafenib caused those events. The record’s counts describe what was entered in the safety summary; they do not support a causal comparison or a broader safety conclusion.

13. What the Result Does, and Does Not, Mean

The record establishes that investigators planned a prospective, single-group Phase IV study of HCV-RNA changes during sorafenib treatment in people with advanced hepatocellular carcinoma and chronic hepatitis C. It defines the primary endpoint as a decline of at least two logs between baseline and any subsequent HCV-RNA measurement, over a timeframe of up to 2 years. It also names time to radiological tumor progression and overall survival as secondary outcomes.

What the record does not establish is whether the primary endpoint was met, how HCV-RNA changed, or what happened for the secondary outcomes. Although the registry lists four outcome measures, it reports zero analyses in the information. A study objective and endpoint definition are not results. Without the primary outcome count, an estimate, and its uncertainty, the magnitude and precision of any observed change cannot be described.

The single-group design also means that any observed change would not have a concurrent control comparison in this record. In general, a change during treatment is not by itself evidence that treatment caused the change. The study’s enrollment of 3 further limits how much a summary could tell readers about a wider population, even if a result were available.

The safety section reports 0 participants with serious adverse events and 3 with other adverse events among 3 at risk. Those counts are descriptive and should not be interpreted as proof of absence or presence of a treatment-caused risk. The registry record does not report deaths in the safety summary.

Accordingly, the most defensible reading is narrow: the registry documents a small study’s question, design, outcome definitions, and selected safety counts, but does not report efficacy analyses. It cannot establish whether sorafenib changed HCV-RNA in this group, nor can it support a treatment recommendation or a conclusion about tumor progression or survival.

14. Why This Trial Matters Statistically

This trial is statistically informative as an example of how a precise biological question can coexist with limited inferential information. The primary endpoint is clearly expressed as a participant-level threshold: a decline in HCV-RNA of at least two logs from baseline to a later measurement. That definition makes the intended event understandable, while also illustrating how a threshold can compress a time-varying laboratory measure into a yes-or-no classification.

The single-group structure is central to interpretation. It can support description of measurements during treatment, but it does not create a concurrent counterfactual comparison. A reader must distinguish evidence that a change occurred from evidence about why it occurred. This distinction applies generally to uncontrolled before-and-after observations.

The registry also highlights the importance of results transparency. It lists an enrollment of 3 and four outcome measures, yet reports zero analyses in the information. As a result, readers can identify the primary question but cannot evaluate an efficacy estimate, its precision, or the relationship between primary and secondary findings. The terminated status adds context about the record but does not explain the absence of analyses or the reason the study ended.

Finally, planning calculations need to be separated from study results and actual design. The sample-size section uses stated hypothetical assumptions, including equal allocation between two arms, even though the registered study is single-group. Such illustrations can help explain how design choices affect required sample sizes, but they do not change the trial structure or fill gaps in the reported analysis.

The statistical lesson is therefore about disciplined interpretation: define the endpoint, identify the design, check what results are actually reported, and keep uncertainty and causal claims within the limits of the evidence.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation specific to this record is the absence of reported efficacy analyses. The registry identifies the primary endpoint and secondary outcomes but does not provide their results. Readers cannot determine how many participants met the HCV-RNA decline definition, inspect measured trajectories, or assess precision.

The enrollment is 3, and the study has no comparator group. A small single-group study offers limited scope for separating treatment-associated changes from other explanations or for generalizing observations beyond the enrolled participants. The record does not provide participant characteristics that would allow readers to assess how closely the group represents the population named in the title.

The endpoint refers to any subsequent measurement during a timeframe of up to 2 years. The registry information does not specify the measurement schedule, the laboratory procedures, or how incomplete follow-up and missing measurements were handled. Without those details, readers cannot evaluate how consistently participants could be classified under the endpoint definition.

The record states that the study was terminated, but the reason is not reported. It also does not report a sample-size justification, statistical analysis plan, interim analyses, stopping rules, multiplicity approach, or analysis populations. These omissions prevent a fuller assessment of whether the planned analysis matches the study question and how results would have been interpreted.

The safety summary provides counts but not event descriptions or deaths. The available information therefore supports only a narrow description of the reported categories, not a complete safety assessment or causal attribution.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) — NCT01849588.
• Registry record last updated 2017-04-19; status last verified 2017-03.
• Results first posted 2017-03-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes a prospective Phase IV, single-group study of sorafenib in people with advanced hepatocellular carcinoma and chronic hepatitis C. Sorafenib was taken orally twice per day. The primary question concerned a decline in HCV-RNA of at least two logs between baseline and any subsequent measurement, within a timeframe of up to 2 years.

The record lists enrollment of 3, status as terminated, and study dates of 2013-05 and 2016-12 for start and primary completion. It names time to radiological tumor progression and overall survival as secondary outcomes. No efficacy analyses are reported in the information. The safety summary records 0 participants with serious adverse events and 3 with other adverse events among 3 at risk; deaths are not reported in the registry record.

The record does not provide the reason for termination, statistical analysis plan, missing-data procedures, or sample-size justification. Its findings should therefore be read as a description of the study’s aims and posted counts, not as a comparative estimate of treatment effect.